Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...
The US Food and Drug Administration (FDA) on Monday finalized guidance to pharmaceutical and biotech sponsors looking for more advice on when non-inferiority studies demonstrating effectiveness of an ...
Randomized controlled trial of the efficacy of lymph node dissection on stage IIICr of cervical cancer (CQGOG0103). Background: Minimally invasive surgery (MIS) is associated with improved ...
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious ...
FAST III was initiated five years ago to evaluate whether revascularization guided by angiography–based FFR using CAAS vFFR (vessel Fractional Flow Reserve) delivers therapeutic outcomes comparable to ...
ONS-5010 shows non-inferiority to Lucentis at 12 weeks; BLA resubmission planned for Q1 2025, with $20.4M in proceeds expected. ONS-5010 demonstrated non-inferiority to ranibizumab at week 12, ...
Functional impairments, fatigue, and pain in newly diagnosed solid-tumors: Retrospective path analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results